MEtronomic TrEatment Option in Advanced bReast cAncer
Status:
Active, not recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, randomized phase II trial that will randomise women with ER-positive,
HER2-negative (Human Epidermal Growth factor Receptor 2-negative) metastatic or locally
relapsed breast cancer in a ratio of 1:1 to receive a metronomic regimen of vinorelbine plus
cyclophosphamide and capecitabine, or the conventional paclitaxel monotherapy.